Kyle Doherty

Articles

Venetoclax/Obinutuzumab Continues to Show Efficacy in Unfit Patients with CLL

June 30, 2022

An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.